Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 20/20 | 0.79 |
| ▸ | NR1H2 | P55055 | 13/20 | 0.79 |
| ▸ | RXRA | P19793 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | VHL | P40337 | 1/20 | 0.79 |
| ▸ | RECQL | P46063 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22592725 | 0.90 | NR1H3 (0.65) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL29383609 | 0.88 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL29359875 | 0.88 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL2110041 | 0.88 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL29802701 | 0.87 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL29378086 | 0.87 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL320637 | 0.87 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL16298957 | 0.87 | NR1H3 (0.79) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL18581814 | 0.86 | NR1H3 (0.77) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL4097245 | 0.86 | NR1H3 (0.71) | NR1H3NR1H2RXRAMEN1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | THE ROCKEFELLER UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | THE ROCKEFELLER UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3091970-B1 | LXR AGONISTS AND USES THEREOF | RGENIX INC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10669296-B2 | LXR agonists and uses thereof | RGENIX, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669296-B2 | LXR agonists and uses thereof | RGENIX, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2019-01-31 | — | — | US | disclosed |
| US-20170066791-A1 | LXR AGONISTS AND USES THEREOF | INSPIRNA, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170066791-A1 | LXR AGONISTS AND USES THEREOF | INSPIRNA, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170066791-A1 | LXR AGONISTS AND USES THEREOF | INSPIRNA, INC. | 2017-03-09 | — | — | US | disclosed |
| EP-3091970-A1 | LXR AGONISTS AND USES THEREOF | Rgenix, Inc. (US) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015106164-A1 | LXR AGONISTS AND USES THEREOF | RGENIX, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669296-B2 | LXR agonists and uses thereof | NR1H3, NR1H2, NR1H4 | NR1H3 1/4885NR1H2 2/4885RXRA 13/4885 |
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | NR1H3, NR1H2, MCL1 | NR1H3 1/4885NR1H2 2/4885RXRA 20/4885 |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | NR1H3 1/4885NR1H2 2/4885RXRA 20/4885 |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | NR1H3 1/4885NR1H2 2/4885RXRA 20/4885 |
| US-20170066791-A1 | LXR AGONISTS AND USES THEREOF | NR1H3, NR1H2, NR1H4 | NR1H3 1/4885NR1H2 2/4885RXRA 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.